Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · October 01, 2023

Effect of Saroglitazar, a Dual PPAR α/γ Agonist, on the Serum Lipid Profile in Patients With Non-Cirrhotic NAFLD

Clinical Gastroenterology and Hepatology


Additional Info

Clinical Gastroenterology and Hepatology
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis
Clin. Gastroenterol. Hepatol. 2023 Sep 01;21(10)2597-2605.e2, MS Siddiqui, D Parmar, F Sheikh, SK Sarin, L Cisneros, S Gawrieh, T Momin, A Duseja, AJ Sanyal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading